VANCOUVER, British Columbia, May 28, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE:
LB6A.F) (the “Company” or “Isodiol”), a global CBD
innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical
industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, announces the closing of the strategic
non-brokered private placement, for total proceeds of $18,000,000.
“We are extremely pleased to close this strategic investment,” said CEO of Isodiol, Marcos Agramont. “With
this additional funding, the Company is now well positioned to further execute its plan of aggressive global expansion and also
continue to be a global CBD innovator. International markets present many opportunities for the Company including new market
channels, university collaborations, clinical studies, and ultimately, increased revenues.”
The Company will use the proceeds of the Private placement primarily for global expansion, including the
recently announced expansion in the UK and China.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade
phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure,
pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin
care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was
announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its
phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward-looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the
forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.